References
- Wagner HN Jr. Molecular nuclear medicine: the best kept secret in medicine. J Nucl Med 1997; 38(8): 15–7N, 36N, 38N passim
- Conti PS, Keppler J. New indications give PET a lift after struggle over regulatory and reimbursement issues. Diagn Imaging 2000; 22(1): 40–7
- Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30(3): 150–85
- Delbeke D, Patton JA, Martin WH, et al. Positron imaging in oncology: present and future. Nucl Med Annu 1998: 1–50
- Patton JA. Instrumentation for coincidence imaging with multihead scintillation cameras. Semin Nucl Med 2000; 30(4): 239–54
- Bax JJ, Patton JA, Poldermans D, et al. 18-Fluorodeoxyglucose imaging with positron emission tomography and single photon emission computed tomography: cardiac applications. Semin Nucl Med 2000; 30(4): 281–98
- Bischof Delaloye A. Radioimmunoimaging and radioimmunotherapy: Will these be routine procedures? Semin Nucl Med 2000; 30(3): 186–94
- Nabi HA. Radiolabeled antibodies in clinical nuclear medicine: a technology coming of age. Nucl Med Annu 1993: 1–28
- Morton DL, Wen D, Wong JH, et al. Technical details of intraoperative mapping for early stage melanoma. Arch Surg 1992; 127: 392–9
- Glass EC, Essner R, Giuliano AE. Sentinel node localization in breast cancer. Semin Nucl Med 1999; 29(1): 57–68
- Alazraki NA, Styblo T, Grant S, et al. Breast cancer sentinel lymph node lymphoscintigraphy: comparison of subdermal and peritumoral injection. (Abstr) J Nucl Med 1999; 40(5 Suppl): 59P
- Guiliano AE, Dale PS, Roderick RT, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222(3): 394–401
- Boerman OC, Oyen WJ, Corstens FH. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin Nucl Med 2000; 30(3): 195–208
- Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phel] and [123I-Tyr3] octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20(8): 716–31